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1University of Kentucky College of Medicine Markey Cancer Center, 800 Rose Street, Lexington, 
KY, 40536.
2Department of Physiology, 800 Rose Street, Lexington, KY, 40536.
3Department of Toxicology and Cancer Biology, 800 Rose Street, Lexington, KY, 40536.
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Abstract
Loss-of-function melanocortin 1 receptor (MC1R) polymorphisms are common in UV-sensitive 
fair-skinned individuals and are associated with blunted cAMP second messenger signaling and 
higher lifetime risk of melanoma because of diminished ability of melanocytes to cope with UV 
damage. cAMP signaling positions melanocytes to resist UV injury by up-regulating synthesis of 
UV-blocking eumelanin pigment and by enhancing the repair of UV-induced DNA damage. cAMP 
enhances melanocyte nucleotide excision repair (NER), the genome maintenance pathway 
responsible for the removal of mutagenic UV photolesions, through cAMP-activated protein 
kinase (protein kinase A)-mediated phosphorylation of the ataxia telangiectasia mutated and Rad3 
related (ATR) protein on the S435 residue. We investigated the interdependence of cAMP-
mediated melanin upregulation and cAMP-enhanced DNA repair in primary human melanocytes 
and a melanoma cell line. We observed that the ATR-dependent molecular pathway linking cAMP 
signaling to the NER pathway is independent of MITF activation. Similarly, cAMP-mediated up-
regulation of pigment synthesis is independent of ATR, suggesting that the key molecular events 
driving MC1R-mediated enhancement of genome maintenance (e.g. PKA-mediated 
phosphorylation of ATR) and MC1R-induced pigment induction (e.g. MITF activation) are 
distinct.
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Introduction
Loss-of-function polymorphisms in the melanocortin 1 receptor (MC1R) signaling axis 
represent a major inherited risk factor for melanoma1–3, a disease which currently affects 
nearly 1 in 50 people in the United States and accounts for more than 80% of skin cancer 
deaths4. Ultraviolet radiation (UV) is a major environmental driver of melanoma, as 
evidenced by the abundance of “UV-signature” pyrimidine transitional mutations in many 
melanomas5,6. UV signature mutations result from the formation of UV photoproducts 
including cyclobutane pyrimidine dimers (CPDs), which if not repaired in a timely manner, 
can result in mutations and promote carcinogenesis and tumor progression7.
MC1R, a Gs protein-coupled receptor located on the melanocyte cell membrane, is integral 
to physiologic melanocytic UV responses. MC1R signaling results in the accumulation of 
cAMP and activation of cAMP-dependent protein kinase (protein kinase A; PKA)8–11. 
cAMP stimulation increases synthesis of the brown/black UV-blocking pigment 
eumelanin12,13 which accumulates in the epidermis to protect the skin against UV 
injury14,15. Induction of eumelanin synthesis is largely dependent upon PKA-mediated 
phosphorylation of the cAMP responsive binding element (CREB) transcription factor at 
Ser133 and subsequent induction of the microphthalmia-associated transcription factor 
(MITF) protein16,17. In turn, MITF promotes the transcription of melanogenic enzymes 
including tyrosinase and dopachrome tautomerase18,19.
In addition to regulating melanin production, we and others have documented that MC1R 
signaling protects melanocytes from UV damage by pigment-independent pathways, 
specifically by protecting the cell against UV mutagenesis and enhancing genomic 
stability11,20–24. MC1R signaling enhances nucleotide excision repair (NER), the genome 
maintenance pathway responsible for identifying and repairing UV-induced DNA 
photolesions. Recently we reported that the critical molecular event linking MC1R signaling 
to NER is a PKA-mediated post-translational modification of the ataxia telangiectasia 
mutated and Rad3 related (ATR) protein. ATR is a global damage response protein that 
mediates checkpoint blockade of the cell cycle and activates damage repair pathways. When 
a cell is damaged, ATR promotes G2/M checkpoint blockade by phosphorylating Chk1 
kinase25,26. We identified a repair-specific function of ATR downstream of MC1R/cAMP 
signaling. When ATR is phosphorylated by PKA on its S435 residue, it facilitates NER by 
accelerating association of the rate-limiting NER factor xeroderma pigmentosum 
complementation group A protein (XPA) with nuclear UV photolesions11. Thus, in 
melanocytes, PKA-mediated phosphorylation of ATR on the S435 residue changes ATR 
function away from checkpoint signaling to a more DNA repair-specific physiology.
MC1R signaling positions melanocytes to better cope with UV injury by increasing 
eumelanin production and by enhancing genomic stability, however it is unclear whether 
there may be cross-talk between these cAMP-dependent downstream events. MITF is a 
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cAMP-induced transcription that is critical to melanin induction18,19 and increases 
expression of genes associated with NER including RPA2 and POLE2 among others27. 
More recently, MITF was reported to promote Wnt signaling in melanocytes28, raising the 
possibility that MITF may influence signaling events. We therefore sought to determine 
whether MITF is required for MC1R enhancement of NER via PKA-mediated generation of 
ATR-p435S. Similarly, since ATR is a Ser/Thr kinase with a host of potential targets29, we 
explored whether ATR kinase function may impact MC1R-induced pigment enzyme 
induction and eumelanin synthesis. We found that basal and cAMP-accelerated NER 
kinetics are MITF-independent and that MC1R-mediated upregulation of tyrosinase and 
melanin synthesis is independent of ATR kinase function. Our findings suggest that cAMP-
mediated induction of eumelanin synthesis and acceleration of NER diverge downstream of 
MC1R signaling and offer the opportunity of exploiting DNA repair benefit for increasing 
resistance of melanocytes to carcinogenic degeneration independent of melanin induction.
Methods
Cell lines and pharmacologic drugs
Transformed melanoma SK-MEL-2 (ATCC) cells and primary human melanocytes (Coriell 
Institute for Medical Research) were cultured in Roswell Park Memorial Institute (RMPI) 
media (Life Technologies) with 10% fetal bovine serum and Cascade Biologics Medium 254 
(Life Technologies) respectively. Cells were not deprived of serum before use in 
experiments. Forskolin (LC Laboratories) and VE-821 (Selleckchem) were utilized as 
indicated. siRNA targeted to ATR (Dharmacon) and MITF (Dharmacon) were performed 
according to the manufacturer’s instructions.
UV exposure
Cells were treated with 0.1% ethanol vehicle, 10 µM forskolin, 10 µM VE-821, or a 
combination of 10 µM forskolin and 10 µM VE-821 as indicated for 1 hour prior to UV 
exposure. Cells were exposed to a double bank of UVB lamps (UV Products, Upland, CA). 
UV emittance was measured with a Model IL1400A handheld flash measurement 
photometer (International Light, Newburyport, MA) equipped with separate UVB 
(measuring wavelengths from 265–332 nm; peak response at 290 nm) and UVA (measuring 
wavelengths from 315–390 nm; peak response at 355 nm) corresponding to International 
Light product numbers TD# 26532 and TD# 27108 respectively. Spectral output of the 
lamps was determined to be roughly 75% UV-B and 25% UV-A. Media was removed from 
the cells prior to exposure, and cells were exposed to a dose of 10 J/m2 UVB (unless 
otherwise stated).
Antibodies
Antibodies directed against pSer435-ATR were generated against the peptide 
CPKRRR(pS)SSLNPS (Amsbio) as previously reported11. Commercially available 
antibodies included anti-CPD (Kamiya Biomedical), anti-CREB (Cell Signaling), MITF 
(Cell Signaling) anti-pSer133-CREB (Cell Signaling), anti-Chk1 (Cell Signaling), anti-
pSer317-Chk1 (Cell Signaling), and anti-tryosinase (Santa Cruz).
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pSer435-ATR detection
pSer435-ATR kinase assays were performed as described24 using the biotinylated ATR 
peptide substrates CPKRRRLSSSLNPS (Genscript). Cells were plated in a 6 well plate and 
treated with ethanol vehicle or 10 µM forskolin for 1 hour prior to harvesting. 100 µM 
biotinylated ATR peptide substrate was added to a strepavidin-coated 96 well plate. 20 µg of 
whole cell lysate was added to the wells in 40 mM Tris-HCL (pH 7.5), 10 mM MgCl2, 1 
mM dithiothreitol (DTT), 100 µg/mL bovine serum albumin, and 10 uM ATP. The kinase 
reaction was performed at 30°C. The reaction was terminated via the addition of 10 µL of 
100 mM EDTA at 1 hour. PKA phosphorylation was measuring utilizing the anti-pSer435-
ATR primary antibody. The primary antibody was conjugated to an HRP-conjugated anti-
rabbit secondary antibody (Abcam) for 1 hour followed by the addition of QuantaBLu 
(Pierce). Fluorescence was detected by plate reader via excitation at 315 nM and emission at 
400 nM.
L-DOPA staining and pigment quantification
Cells were plated at a density of 3 × 105 per well in a 6 well plate, treated with vehicle or 
forskolin (as described elsewhere), washed in PBS and then fixed in 4% paraformaldehyde 
for 10 minutes. After three washes in PBS, L-DOPA (10mM) was added to the cells for 2h at 
37°C, followed by a final fixation step in 4% paraformaldehyde for 10 minutes. Photographs 
were then taken of cell pellets before cells were dissolved in soluene-350 (Perkin Elmer): 
water (9:1;v/v) for 10 minutes and heated at 95°C for 30 minutes. Soluene-350 supernatants 
were analyzed at 492 nm on a Multiskan MCC/340 (Thermo Labsystems) plate reader.
SiRNA
Cells were treated with pooled siRNA directed to ATR (ON-TARGET plus SMARTpool; 
Dharmacon) and MITF (ON-TARGET plus SMARTpoolDharmacon). siRNA was 
transfected following the manufacturer's protocol. The siRNA was diluted in serum-free 
medium such that the final concentration was 25 nM. The DharmaFECT solution was 
diluted such that 5 uL was added per well (6 well plate). SK-MEL-2 cells were treated with 
siRNA directed to ATR for 96 hours prior to treatment with vehicle or forskolin. SK-MEL-2 
cells and primary human melanocytes were treated with siRNA directed to MITF for 72 
hours prior to treatment with vehicle or forskolin as indicated. Duration of vehicle or 
forskolin treatment is indicated in each experiment. siRNA knockdown was confirmed at the 
time point indicated for each experiment.
Nucleotide excision repair kinetics
Immuno slot blots were performed on whole cell lysates with 6,4 and CPD antibodies via 
standard methods11. Genomic was isolated using the DNEasy Qiagen Kit per manufacturer’s 
instructions. DNA concentration was determined by Nanovue nanodrop (GE Healthcare) 
reading. Equal loading of DNA was confirmed by 4',6-Diamidino-2-Phenylindole, 
Dihydrochloride (DAPI, 1mg/ml; Thermo Fisher) staining. DNA was denatured at 95°C for 
10 minutes, and 0.1 µg was loaded per well on a slot blot apparatus (BioRad) on a 
nitrocellulose membrane (BioRad). Wells were washed with TE and suction was applied 
until dry. Membranes were baked (80°C, 1h), blocked in 5% milk (20°C, 1h, TBS buffer, 
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0.5% Tween), incubated with anti-CPD (Cosmo Biosciences, 1:1,000 dilution, 4°C, 
overnight), washed, incubated in secondary antibody (HRP-anti-mouse, Abcam, 1:10,000, 
20°C, 1h) prior to visualization by ECL using the STORM system.
Immunoblotting
Immunoblots were performed on whole cell lysates in radioimmunoprecipitation assay 
(RIPA) buffer. Cells were lysed in RIPA buffer for 20 minutes at 4°C. Protein concentration 
was determined via Bradford protein assay (Life Technologies). 10–30 µg of protein were 
loaded onto a 4–20% gradient SDS-polyacrylamide gel (SDS-PAGE) (BioRad). 
Immuoblotting was either performed using the Odyssey Infrared Imaging System (Li-Cor) 
or STORM imaging system (GE Healthcare) and analyzed using ImageJ.
Statistics and data analysis
One-way ANOVA with Tukey post-hoc test and two-way paired ANOVA analysis were 
performed using GraphPad Prism 5.0 (GraphPad Software, CA). Data were considered 
statistically significant if p values were less than 0.05 from multiple independent 
experiments.
Results
MITF depletion does not affect NER kinetics
SK-MEL-2 melanoma cells or primary human melanocytes (PHMs) were pre-treated with 
either scrambled or siRNA directed to MITF prior to incubation with forskolin, an activator 
of adenylyl cyclase. Accumulation of pSer435-ATR was measured by kinase assay as 
previously described11. Forskolin promoted 6.0-fold and 4.0-fold inductions of ATR 
phosphorylation of Ser435 in SK-MEL-2 or PHMs respectively, and levels of pSer435-ATR 
were not influenced by siRNA-mediated MITF depletion in either cell type (Fig.1A, B). 
Therefore we conclude that PKA-mediated generation of ATR-pS435 is MITF-independent. 
To directly determine whether MITF is required for MC1R-enhanced NER, we measured the 
effect of MITF depletion on basal and cAMP-enhanced repair of UV-induced photolesions. 
SK-MEL-2 cells or PHMs were treated with vehicle control or 10 µM forskolin for 30 
minutes prior to exposure to a sub-lethal dose (10 J/m2) of UVB radiation, and repair of 
CPDs was assessed at 0, 24, 48, and 72 hours. Treatment with forskolin significantly 
accelerated NER in either SK-MEL-2 cells or PHMs, and neither basal repair nor forskolin-
enhanced repair were affected by siRNA-mediated MITF depletion in either cell type (Fig. 
1C,D). These data suggest that MC1R-enhanced NER is MITF independent.
ATR is not required for PKA phosphorylation of CREB
While our results suggested to us that MC1R-enhanced NER is independent of MITF, they 
do not exclude the possibility of signaling pathway cross-talk in which ATR influences 
cAMP-directed melanocyte responses. An early molecular event following cAMP 
stimulation is PKA-mediated phosphorylation of the CREB transcription factor, induction of 
MITF and a variety of downstream pro-differentiation events that follow16,17. To understand 
whether ATR kinase function is required for cAMP-mediated phosphorylation of CREB, we 
quantified levels of PKA-phosphorylated CREB in SK-MEL-2 cells or PHMs treated with 
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10 µM forskolin. cAMP stimulation led to increased levels of CREB-pS133 at 1h (2.4-fold 
induction for SK-MEL-2 cells; 2.6-fold induction for PHM), and addition of the ATR kinase 
inhibitor VE-821 did not affect CREB-pS133 levels (Fig. 2A–D). As a control to ensure 
VE-821 inhibited ATR, we evaluated total and ATR-phosphorylated forms of the checkpoint 
kinase Chk1. At the dose used, VE-821 inhibited Chk1-pS317 levels without affecting total 
Chk1 levels (insets, Fig. 2A,C), indicating that the drug blocked ATR kinase function. 
Similar results were noted with siRNA-mediated ATR depletion in SK-MEL-2 cells (Suppl. 
Fig. 1). Together, these results suggest that ATR is not required for PKA-mediated CREB 
phosphorylation downstream of cAMP induction.
ATR does not impact cAMP-induced MITF activation
To determine whether cAMP-induced MITF activation requires ATR, SK-MEL-2 cells or 
PHMs were incubated with forskolin and MITF levels were quantified through 6h in the 
presence or absence of the ATR kinase inhibitor VE-821. We noted increased MITF 
expression by forskolin was not impacted by the ATR kinase inhibitor VE-821 (Fig. 3A–D). 
These findings suggest that ATR is dispensable for cAMP-mediated MITF induction.
ATR inhibition does not interfere with cAMP-mediated pigment induction
To directly determine whether ATR was required for MC1R dependent pigmentation, we 
measured the effect of ATR inhibition on cAMP-enhanced pigmentation30. SK-MEL-2 cells 
or PHMs were incubated (2h) in the presence or absence of forskolin (10 µM) and VE- 821 
(10 µM). To assess the impact of ATR inhibition on cAMP-mediated melanin induction, we 
measured pigmentation of SK-MEL-2 cells or PHMs after DOPA staining31. Forskolin 
promoted pigment induction in either cell type, as assessed visually (Fig. 4A,B) or 
spectrophotometrically (Fig. 4C,D). These data suggest that cAMP-induced pigmentation is 
unaffected by ATR kinase function.
Discussion
Inherited loss-of-function MC1R polymorphisms affect millions of individuals and place 
them at greater risk of melanoma1,3. Indeed, the loss of even one functional copy of the 
MC1R gene results in an accumulation of UV mutations in melanoma equivalent to more 
than two decades of life32, supporting a link between MC1R signaling and melanocyte 
genomic stability. Defective pigmentary responses caused by MC1R loss yield a fair-skinned 
and sun-sensitive phenotype12 that facilitates UV penetration into the skin and a tendency 
for episodic UV-induced inflammatory episodes (sunburns)14, both of which favor 
melanoma development33–35. We and others have documented that MC1R loss also results 
in defects in the ability of melanocytes to repair UV photodamage in nuclear 
DNA21,22,24,36,37. This damage, if left unrepaired, causes transitional pyrimidine “UV-
signature” mutations known to cause and promote melanoma development5–7. Thus, MC1R 
signaling, mediated by generation of the second messenger cAMP38, is a global regulator of 
melanocyte UV physiology and UV resistance.
Herein we report that MITF does not appear to be required for cAMP-enhanced NER. 
Although MITF functions as a transcription factor inducing genes involved in NER27, it has 
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also been reported to regulate cell signaling pathways such as Wnt signaling in a positive 
feedback mediated manner and Wnt-mediated increases in vesicular structures and 
endosomal proteins28. Our data suggest that MITF is not necessary for PKA 
phosphorylation of ATR at Ser435, which occurs and exerts its effects within minutes 
following stimulation of melanocytes by cAMP induction11. Furthermore, MITF loss has 
little impact on basal NER kinetics or cAMP-enhanced repair. While Strub and coworkers 
reported that MITF induces expression of RPA, XRCC3 and POLE27, XPA, which is 
considered to be the rate-limiting factor in NER39,40 and the key mediator of MC1R-
enhanced NER11, was not induced by MITF27. Our data, however, do not exclude the 
possibility that MITF influences melanocyte genomic stability in other ways beside the 
cAMP-ATR-XPA repair axis. Indeed, one possibility is cAMP protective effects on cellular 
anti-oxidant levels10,41 since lower amounts of UV-induced free radicals and oxidative 
species would be expected to preserve repair enzyme function by preventing their 
inactivation. Lastly, Mitf levels were documented at the end of the experimental time frame; 
although unlikely, it may be possible that Mitf expression was less inhibited at earlier time 
points.
Data presented here also suggest that non-DNA repair physiologic events downstream of 
MC1R are independent of ATR. Specifically, inhibiting ATR either pharmacologically by 
the kinase inhibitor VE-821 or by siRNA-directed knockdown had no discernable effect on 
phosphorylation of CREB by PKA or basal levels or cAMP-induced activation of MITF 
protein. Moreover, our findings suggest that ATR is not required for cAMP-mediated up-
regulation of pigmentation, however our data do not rule out the possibility that ATR 
function may impact other pigment enzyme expression or function downstream of cAMP 
signaling. The cell lines used in these studies did not appear to express pigment in culture 
either basally or within the time course of our experiments. However it is possible that low 
levels of melanin could have contributed to the formation of “dark photoproducts” through 
oxidative induction of melanin triplet energy state with subsequent formation of CPDs as 
recently described42. Our data did not directly address this as a possibility.
In summary, we have determined that cAMP-mediated augmentation of the melanocyte 
adaptive pigmentation pathway and acceleration of NER appear to diverge at the level of 
PKA as would lie downstream of the melanocortin signaling cascade in melanocytes. There 
is much interest in developing UV-protective and melanoma-preventive strategies based on 
pharmacologic induction of melanocortin/cAMP signaling in the skin43–45, however to date, 
there is no way to uncouple the benefits of enhanced DNA repair and genomic stability with 
pigment enhancement, or possibly other cAMP-directed responses such as melanocyte 
proliferation. Our findings offer the possibility of developing approaches to enhance 
melanocyte genomic stability independent of melanin induction.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. MITF inhibition does not affect PKA-mediated generation of pS435-ATR and has no 
functional impact on melanocyte nucleotide excision repair (NER)
(A,B) SK-MEL-2 melanoma cells (n=3) (A,C) and primary human melanocytes (PHMs; 
n=4) (B,D) were treated with scrambled siRNA or siRNA directed to MITF prior to 
treatment with 10 uM forskolin. Whole cell lysates were collected at 1 hour and pSer435-
ATR levels were determined by kinase assay (A,B). Values not sharing a common letter are 
significantly different as determined by one-way ANOVA and Tukey post-hoc test (p<0.05). 
Data are expressed as mean-fold change over control ± SEM. C,D) Cells were treated with 
scrambled siRNA or siRNA directed to MITF. Cells were treated with 10 uM forskolin for 
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30 minutes prior to treatment with 10 J/m2 UVB radiation. MITF knockdown following 
treatment with siRNA directed to MITF is shown in inset. Significance between control and 
forskolin treatment as determined by two-way paired ANOVA (p<0.05) is denoted by an 
asterisk (*). Data are expressed as mean CPD remaining ± SEM. Insets show degree of 
MITF knockdown by Western blotting.
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Fig. 2. ATR inhibition does not affect PKA phosphorylation of CREB
SK-MEL-2 melanoma cells (n=3) (A–B) and PHMs (n=3) (C–D) were treated with 10 uM 
forskolin, VE821, or a combination of 10 uM forskolin and 10 uM VE-821. Whole cell 
lysates were collected 1 hour following treatment and immunoblotted for pSer133-CREB. 
B,D) Composite densitometry quantification of immunoblots (n=3 per condition) in A,C. 
Values not sharing a common letter are significantly different as determined by one-way 
ANOVA and Tukey post hoc test (p<0.05). Data are expressed as mean-fold change over 
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control ± SEM. Panel insets show effect of VE-821 on UV-mediated Chk1 phosphorylation 
(pChk1 S313).
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Fig. 3. Pharmacologic ATR inhibition does not interfere with cAMP-induced Mitf activation
SK-MEL-2 melanoma cells (n=3) (A–B) and PHMs (n=3) (C–D) were treated with 10 uM 
forskolin, VE821, or a combination of 10 uM forskolin and 10 uM VE-821. Whole cell 
lysates were collected 1 hour following treatment and immunoblotted for Mitf. B,D) 
Composite densitometry quantification of immunoblots (n=3 per condition) in A,C. NS 
denotes that no significant difference was observed between experimental groups as 
determined by one-way ANOVA and Tukey post hoc test. Data are expressed as mean-fold 
change over control ± SEM.
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Fig. 4. ATR inhibition does not interfere with cAMP-induced pigment induction
SK-MEL-2 melanoma cells (n=3) (A,C) and primary human melanocytes (PHMs; n=4) 
(B,D) were treated with vehicle controls 10 uM VE-821 or 10 uM forskolin. Cells were 
collected, incubated with L-DOPA (see methods) and pelleted after 2h. A,B) photographs of 
microcentrifuge tubes showing cell pellets of indicated conditions. C,D) Cells were lysed in 
soluene-350 solution and spectrophotometry of supernatants was quantified at 492 nm. 
Values not sharing a common letter are significantly different as determined by one-way 
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ANOVA and Tukey post hoc test (p<0.05). Data are expressed as mean-fold change over 
control ± SEM.
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